Breast Cancer Clinical Trial
— IBMCOfficial title:
Tobacco and Alcohol Risk Reduction for Women Treated for Breast Cancer and Partner Involvement : Benefits of a Brief Motivational Couple-based Intervention.
This study will examine the benefits of involving partner in a Screening, Brief Intervention and Referral to Treatment (SBIRT) program for tobacco and alcohol for women treated for breast cancer. Using a two-arm randomized trial (couple brief motivational intervention (CBMI) versus individual brief motivational intervention (IBMI) with repeated measures at 6 weeks, 3 and 6 months.
Status | Not yet recruiting |
Enrollment | 320 |
Est. completion date | August 2022 |
Est. primary completion date | August 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - for the breast cancer patient: patients treated for a first breast cancer; Karnofsky Index> 70; - for both patient and partner: =18 years old; smoking more than or equal to 1 cigarette/day; - without ongoing treatment for current substance-related disorders; having a good understanding of the French language; - able to express consent to benefit from intervention focused on smoking cessation; - having an email address and internet access at home. Exclusion Criteria: - Refusal of the patient that his/her partner participates or refusal of the partner to participate - Individual deprived of liberty, under guardianship or trusteeship - Individual with a dementia or psychiatric disorder that could compromise informed consent and commitment in different times of the study |
Country | Name | City | State |
---|---|---|---|
France | Institut Bergonie | Bordeaux |
Lead Sponsor | Collaborator |
---|---|
Institut Bergonié | Ligue contre le cancer, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tobacco 7-day point prevalence abstinence (PPA) at 6 months | 6 months | ||
Secondary | Tobacco 7-day point prevalence abstinence (PPA) at 6 months | 6 weeks | ||
Secondary | Tobacco 7-day point prevalence abstinence (PPA) at 6 months | 3 months | ||
Secondary | Quality of life as per EORTC QLQ-C30 | European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 - Aaronson et al. JNCI 1993 | 6 months | |
Secondary | Quality of life as per EORTC QLQ-C30 | European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 - Aaronson et al. JNCI 1993 | 6 weeks | |
Secondary | Quality of life as per EORTC QLQ-C30 | European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 - Aaronson et al. JNCI 1993 | 3 months | |
Secondary | Nicotine dependence measured using the Fageström (1978) test | 6 months | ||
Secondary | Nicotine dependence measured using the Fageström (1978) test | 6 weeks | ||
Secondary | Nicotine dependence measured using the Fageström (1978) test | 3 months | ||
Secondary | Alcohol consumption based on the AUDIT scale | Alcohol Use Disorders Test short version - Saunders JB, Aasland OG, Babor TF, de la Fuente JR and Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption II. Addiction 1993; 88:791-804. | 6 months | |
Secondary | Alcohol consumption based on the AUDIT scale | Alcohol Use Disorders Test short version - Saunders JB, Aasland OG, Babor TF, de la Fuente JR and Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption II. Addiction 1993; 88:791-804. | 6 weeks | |
Secondary | Alcohol consumption based on the AUDIT scale | Alcohol Use Disorders Test short version - Saunders JB, Aasland OG, Babor TF, de la Fuente JR and Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption II. Addiction 1993; 88:791-804. | 3 months | |
Secondary | Psychological distress Symptom Checklist-90-R | SCL-90-R, Derogatis et al. Psychopharmacol Bull. 1973. | 6 months | |
Secondary | Psychological distress Symptom Checklist-90-R | SCL-90-R, Derogatis et al. Psychopharmacol Bull. 1973. | 6 weeks | |
Secondary | Psychological distress Symptom Checklist-90-R | SCL-90-R, Derogatis et al. Psychopharmacol Bull. 1973. | 3 months | |
Secondary | Scores of conjugal adaptability and cohesion with The Family Adaptability and Cohesion Evaluation Scale (FACE III). | 6 months | ||
Secondary | Scores of conjugal adaptability and cohesion with The Family Adaptability and Cohesion Evaluation Scale (FACE III). | 6 weeks | ||
Secondary | Scores of conjugal adaptability and cohesion with The Family Adaptability and Cohesion Evaluation Scale (FACE III). | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |